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Abstract 
Pediatric movement disorders may present with psychiatric symptoms at many points during the 
course of the disease.  For the relatively common pediatric movement disorder, Tourette syndrome, 
psychiatric comorbidities are well-described and treatment is well-studied.  Treating these comorbidities 
may be more effective than treating the movements themselves.  For more uncommon movement 
disorders, such as juvenile-onset Huntington disease, treatment of psychiatric comorbidities is not well-
characterized, and best practice recommendations are not available.  For the least common movement 
disorders, such as childhood neurodegeneration with brain iron accumulation, psychiatric features may be 
nonspecific, so that underlying diagnosis may be apparent only after recognition of other symptoms.  
However, psychiatric medication, psychotherapy, and psychosocial support for these disorders may prove 
helpful to many children and adolescents. 
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Introduction 
Pediatric movement disorders vary widely in their presentation, and psychiatric features may 
appear at many points in the course of the disease.  In some movement disorders, psychiatric symptoms 
may present first, as is often seen in Huntington disease (HD), where mood symptoms may predominate, 
or in Tourette syndrome (TS), in which tics are often preceded by attention-deficit symptoms and followed 
by obsessive-compulsive behaviors. In some cases, what appears to be a pediatric psychiatric disorder 
eventually declares itself to be a movement disorder with a deteriorating course, clearly different than the 
expected course of a primary psychiatric condition.  
In this review, six pediatric movement disorders with psychiatric features will be discussed: TS, 
Sydenham chorea (SC), juvenile-onset HD, pantothenate kinase-associated neurodegeneration (PKAN), 
phospholipase A2 group 6-associated neurodegeneration, and stereotypic movement disorders.  For TS, 
good evidence is available for best-practice treatment of tics and psychiatric comorbidities. For two of 
these disorders, TS and stereotypic movement disorder, direct psychotherapy of the movement itself may 
be a useful treatment approach.  What is known about comorbidities, published treatment, and the 
emotional experience of the other, less common and less well-studied disorders will be reviewed in this 
article. 
 
Tourette syndrome (TS) 
 
The psychiatric comorbidities of TS are numerous, well-studied, and often more distressing to 
patients than the tics themselves.  In fact, comorbidity is the rule for TS.  The Tourette Syndrome 
International Database Consortium (TIC database) is the largest source of comorbidity data for TS.  This 
consortium of clinicians from 27 countries has collected data about patients with TS since 1996.  
Diagnoses are ascertained using Diagnostic and Statistical Manual (DSM) criteria.  In the TIC database 
sample of 5060 5- to 17-year-olds, 74.7% of patients had at least one psychiatric comorbidity, with 
attention-deficit hyperactivity disorder (ADHD) by far the most common comorbidity, followed by 
obsessive-compulsive disorder (OCD) (see Table 1).
1
  In a somewhat larger TIC database sample that 
included adults, other significant comorbidities included self-injurious behavior (14%) and poorly 
controlled/explosive angry outbursts (37%).
2
  Many patients with TS have multiple psychiatric 
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comorbidities.  ADHD appears to be a key driver of complex comorbidity in TS: in the child/adult TIC 
database study, the presence of ADHD was associated with increased comorbidity of all studied 
conditions except anxiety disorders.
2
 This distribution of comorbidity mirrors that reported in smaller 
studies.
3, 4
 
 The often complex psychiatric comorbidity experienced by patients with TS poses diagnostic and 
treatment challenges. Patients ultimately developing the “triad” of TS + ADHD + OCD typically present 
with ADHD as preschoolers, soon followed by tics (modal onset 6-8 years), and later by OCD (12 years) 
or obsessive-compulsive behaviors (OCBs), as demonstrated in a longitudinal study of 976 children 
followed over 15 years.
5
  This progression of symptoms can be confusing and upsetting to children and 
their families, sometimes triggering concern that treatment of an earlier condition caused later symptoms, 
for instance, that medications for ADHD led to tics.   
The following sections will review key aspects of recognition and treatment of psychiatric 
comorbidities of TS, closing with a review of behavioral treatments of tics.  Medication treatment of tic 
disorders is reviewed elsewhere in this journal. 
TS: psychoeducation 
Both the American Academy of Child and Adolescent Psychiatry (AACAP) and the European 
Society for the Study of Tourette Syndrome recommend psychoeducation and monitoring of symptoms as 
first-line interventions for patients with TS.
6, 7
  Good psychoeducation for patients and families includes 
review of symptoms, comorbid conditions, and treatment options versus watchful waiting of tics.  The 
natural history of tic disorders should be reviewed.  The news that many patients do not take medication 
for their tics
2
 and that most will find that their tics diminish with age is greatly reassuring to children and 
their families.
6
  Patients and families should be taught to observe the natural waxing and waning of tics, 
watching for tic triggers and stressors that could be modified.   
For many children with TS, school is the most challenging aspect of daily life.  Classroom 
accommodations such as tic breaks, extended time on tests, and no-tolerance policies for bullying can 
reduce stress and possibly tics at school.  Having an “elevator speech” prepared to explain tics to peers 
and teachers can be quite helpful.  In addition, psychoeducation of teachers and peers may reduce 
bullying and ridicule in the classroom.  College students who watched a TS education video reported 
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improved attitudes towards people with tics compared to their peers who watched a generic video.
8
 
However, grade school children shown a similar video did not improve ratings of peers presented with 
TS.
9
   
Excellent support groups for patients with TS are active in many countries, including the Tourette 
Association of America.  These groups provide educational materials for patients, families and teachers, 
as well as support groups and summer camps for youth.  Many children with TS have never met a peer 
with TS, and find interacting with peers who also have TS a great support.   
Some patients with TS will require more than psychoeducation. Treatments for comorbid 
conditions such as ADHD and OCD are often more effective than directly treating tics, and better control 
of these conditions can secondarily reduce stress and tics.  Thus, following psychoeducation, the next 
steps in the TS treatment algorithm would be evidence-based treatment of comorbid conditions, followed 
by non-pharmacologic treatment of tics, and finally by medication treatment of tics.
10
 
 
TS and ADHD 
The medications used most commonly in the management of comorbid tic disorders and ADHD 
are stimulants, alpha-2 agonists, and atomoxetine. Rizzo et al. suggested the following algorithm for 
medication treatment of comorbid ADHD and tic disorders: 1) alpha-2 agonist; 2)  psychostimulant; 3)  
alpha-2 agonist plus psychostimulant, and 4)  atomoxetine “or other medications”.
11
 A limited number of 
other studies also suggest the potential benefit of off-label combination therapy for ADHD with both 
stimulants and atomoxetine, although further studies are needed to confirm its benefit.
11,12
  Tachycardia 
may be more problematic with this combination therapy than with stimulants or atomoxetine alone. 
 TS and ADHD: Alpha-2 agonists 
Clonidine has been shown to be effective (level A evidence) in two controlled studies.  Clonidine 
reduced both ADHD symptoms (hyperactivity and impulsivity) and TS symptoms (motor tic severity and 
tic counts) in a study of 41 adults and children with TS.
13  
 In the multicenter double-blind randomized trial 
by the Tourette Syndrome Study Group, clonidine, methylphenidate, and their combination were 
compared to placebo.
14
 136 children with ADHD and chronic tic disorders participated in the study.  
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Clonidine was particularly helpful for hyperactivity and impulsivity, and methylphenidate for inattention. 
Combination therapy was most effective in reducing tic and ADHD severity.  Despite concerns that 
stimulants could exacerbate tics, tic exacerbation rates were similar in all arms of the study at 20-25%.  In 
fact, tics improved with all active medications (see Stimulants below). 
Guanfacine, another alpha-2 agonist, has demonstrated efficacy in TS +/- ADHD in one 8-week 
controlled study.  Teacher ratings of ADHD were significantly better for subjects on guanfacine, but parent 
ratings of hyperactivity were not significantly improved versus placebo.
15
   
Alpha-2 agonists can cause sedation, sleep disturbance, fatigue, dizziness, irritability, and 
hypotension. Blood pressure monitoring is necessary.  One tic clinic has reported syncope in 4 of 
approximately 200 normotensive patients on guanfacine, but none in approximately 450 clonidine-treated 
patients.
16
 Both clonidine and guanfacine are available as immediate-release and extended-release 
forms, the latter of which may lead to fewer or milder side effects.
11, 13
  The above studies were completed 
with immediate-release versions.  A recent open-label study of clonidine transdermal patch lacked 
controls and is difficult to interpret, as patients began patch treatment only one week after discontinuing 
previous tic medications, including neuroleptics, and baseline movements may have included withdrawal 
dyskinesias.
17
 
TS and ADHD: Stimulants  
Stimulants such as methylphenidate are highly effective for ADHD (level A evidence). For many 
years, there has been significant concern about using stimulants to treat ADHD in patients with comorbid 
tic disorders, as some patients report tic exacerbations on those agents. In fact, stimulant package inserts 
list tic disorders or family history of tic disorders as contraindications to use of stimulants. These 
contraindications have posed a significant clinical dilemma in the treatment of children with tic disorders 
whose ADHD was significantly impairing.   
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Multiple meta-analyses have reported that stimulants neither trigger nor exacerbate tics in 
children.
18,19,20
  A recent meta-analysis demonstrated that many children with ADHD and comorbid tic 
disorders benefit significantly from stimulants with minimal tic exacerbation. This analysis of 22 studies of 
2,385 children found that tic onset/exacerbation was reported at similar rates for stimulant- (6.5%) and 
placebo-treated youth.  The authors advised, “Clinicians may want to consider re-challenging children 
who report new onset or worsening of tics with psychostimulant use, as these symptoms are much more 
likely to be coincidental rather than caused by psychostimulants”.
20
 In fact, a two-week study assessing 
two cohorts of children with ADHD and Tourette syndrome or chronic motor tic disorder found that 
classroom tic severity and frequency improved in those who received a stimulant compared to placebo, 
according to teacher ratings. Aggression and oppositional defiance showed improvement on 
methylphenidate (immediate release) as well.
21
  
Tics tend to manifest in early school age, when children often start stimulant treatment of ADHD. 
This makes it challenging initially to distinguish the etiology of tics, and whether stimulants have played a 
role. Additionally, tics typically wax and wane in frequency and severity when untreated.  It may be 
difficult to assess the effect of a given medication on these symptoms without a trial lasting several 
months.
11
 
Adverse effects of stimulants that should be monitored include decreased appetite, weight loss, 
sleep disturbance, headaches and dizziness, change in heart rate and diastolic blood pressure, and 
worsening obsessive-compulsive symptoms.
21,22
 If adverse effects are reported after starting a stimulant, 
it is reasonable to switch stimulant families (e.g., change from a methylphenidate agent to an 
amphetamine agent). 
TS and ADHD: Atomoxetine 
Atomoxetine, a non-stimulant selective norepinephrine reuptake inhibitor, increases 
noradrenaline and dopamine in the synaptic cleft, similar to stimulants, and is approved for use in ADHD.  
Although limited evidence exists for tic efficacy, one double-blind placebo-controlled industry-funded 
study showed an effect size of 0.40 for reduction in Yale Global Tic Severity Scale total scores.
23,24
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Atomoxetine side effects include decreased appetite, weight loss, nausea, and tachycardia; blood 
pressure and pulse monitoring is recommended.
23,25,26
 Atomoxetine, unlike stimulants, is sedating, and 
carries two black-box warnings for suicidal thinking in patients younger than 25 years of age and for rare 
jaundice with associated liver enzyme elevations.  
TS and OCD 
Like TS, OCD is characterized by unwanted repetitive behaviors.  However, in OCD, repetitive 
behaviors, or compulsions, are triggered by intrusive thoughts (obsessions) rather than the sensory urges 
that often precede tics.
27
 Obsessive thoughts precede compulsions, and sensory urges precede tics.  
However, TS and OCD symptoms overlap in some patients.  Patients with tics and OCD may report 
experiencing some repetitive behaviors which cannot be clearly classified, or which seem intermediate 
between compulsions and tics.
28
  
Tic-related OCD tends to present in childhood, particularly in boys, while non-tic-related OCD 
tends to present later in life.
27
 The obsessions and compulsions reported by patients with OCD + TS differ 
from those reported by patients with OCD – TS.  Patients with OCD + TS are more likely to report 
compulsions to blurt obscenities, count, or self-harm, while patients with OCD only are more likely to 
endorse compulsions to order, clean, or arrange.
29,30
  
 
TS and OCD Treatment: the Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) 
Psychotherapy and medication management have both demonstrated efficacy in pediatric OCD. 
The Pediatric Obsessive-Compulsive Disorder Treatment Study (POTS) is a key study in the treatment of 
pediatric OCD.
31
 While selective serotonin reuptake inhibitors (SSRIs) and exposure and ritual prevention 
therapy (ERP), a form of cognitive-behavioral therapy (CBT) specific to OCD, were well-established in 
adults, this large-scale study answered several important pediatric questions, including relative efficacy of 
therapy versus SSRI medication, and the impact of tics on treatment response. 
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POTS is a multisite randomized controlled trial of 112 youth (7-17 years old) with OCD.  The 
study compared ERP, sertraline (titrated to a maximum dose of 200 mg daily), combined ERP and 
sertraline, and placebo.  All active treatments outperformed placebo on the Children’s Yale-Brown 
Obsessive-Compulsive Scale (CY-BOCS), the primary outcome measure.
32
 ERP combined with sertraline 
(53.6%, 95% CI 36-70%) produced similar outcomes to ERP alone (39.3%, 95% CI 24-58%), but better 
than sertraline alone (21.4%, 95% CI 10-40%). ERP alone led to significantly greater remission rates than 
did placebo.
31
 ERP continuation studies have shown up to 9-month durability of this improvement, with 
two-thirds of patients maintaining improvement even after medication discontinuation.
33,34,35
  
The POTS II randomized controlled trial then studied augmentation management in children 
already on an SSRI, comparing full ERP (as provided in POTS I) to briefer ERP instructions given by 
prescribers in medication management clinics.  Full ERP, but not the abbreviated ERP instruction, 
augmented medication effects significantly as measured by CY-BOCS.
36,37,38
 
In the POTS studies, ERP worked just as well for patients with tic-related OCD as it did for 
patients with OCD only. However, the comorbidity of tics with OCD appeared to alter treatment response 
to sertraline treatment.  Patients with comorbid tics responded no better to sertraline than to placebo, as 
measured by CY-BOCS score at 12 weeks. Thus, ERP is an essential component of therapy for patients 
with tic-related OCD.
39 
The following two sections further address psychotherapy and medication protocols for pediatric 
OCD. Typically, these protocols have been developed for OCD alone, rather than directly addressing 
treatment strategies for OCD + TS. 
Best-Practice OCD Treatment: ERP Efficacy and Techniques 
Evidence-based treatment guidelines and the American Academy of Child and Adolescent 
Psychiatry practice parameters recommend ERP therapy as first-line treatment of mild to moderate OCD, 
and ERP combined with an SSRI for moderate to severe OCD in young people.
31,39-42
 Multiple studies, 
including the POTS trials,  and meta-analyses suggest that ERP leads to equal or better outcomes 
compared to pharmacotherapy alone and has more enduring effects.
31,41,43
   Like medications for OCD, 
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ERP has been shown to alter brain function, decreasing caudate nucleus glucose metabolism in patients 
with OCD
44
 and increasing neurotransmitter levels, including glutamate/glutamine, and N-acetyl-
aspartate/N-acetyl-aspartyl-glutamate.
45
  
ERP is focused on extinction: repeated exposure to the anxiety-provoking stimulus without 
engagement in ritualized response reduces distress.  Exposure is gradual, moving from least to most 
severe anxiety-provoking stimuli, using a symptom hierarchy that ranks predicted distress for each item or 
task.
46
  For instance, a child with contamination fear might start therapy by touching doorknobs 
(exposure) without immediately washing her hands (ritual prevention), and gradually work up to touching 
the most-feared items on the child’s symptom hierarchy, such as public toilets.  Other components of ERP 
include psychoeducation about OCD and cognitive strategies such as externalizing the disease, 
constructive self-talk, and restructuring. For children, parental involvement in therapy sessions and 
coaching between therapy visits strengthens therapeutic success.
43
   ERP can be delivered in weekly 
outpatient sessions, or in more intensive programs.  Modifications have also been published for group 
and family sessions, as well as treatment of very young children with their parents.
43,47-49
 
Unfortunately, many barriers prevent wider implementation of ERP.
50,51
 Access to ERP-trained 
therapists is limited, particularly therapists trained to work with children.
52
 Patients with OCD of all ages 
may be anxious about confronting their fears and so may not follow through with ERP. Local therapist 
skills in ERP may not be optimal due to low OCD case volume.  Some families find it is cheaper to obtain 
medication management than ERP, and some practices may steer their providers towards providing 
shorter medication management visits rather than longer therapy visits.
31,53,54
 
Best-Practice OCD Treatment: Pharmacologic Therapy  
It is not uncommon for patients with OCD to start with medication treatment only due to limited 
access to ERP.  However, as noted in the section on the POTS trials, efficacy of these medications for 
children with OCD + TS may be less robust than for patients with OCD only. 
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 The most studied and recommended pharmacologic agents for OCD are SSRIs.
31,38,55-57
   Based 
on the available evidence, the following algorithm for pharmacologic management of pediatric OCD is 
suggested: 1) Food and Drug Administration (FDA)-approved SSRI monotherapy; 2) second SSRI; 3) 
partially-effective SSRI augmented with an atypical antipsychotic; 4) clomipramine; 5) combination of 
SSRI and clomipramine.
58
  
The first-line pharmacotherapy, SSRIs, have been shown to be effective for OCD, with a tolerable 
adverse effect profile, in multiple trials. Interestingly, studies of brain morphometry show that fluoxetine 
improves OCD grey matter volume deficits.  A matched CBT group also clinically improved but did not 
show these grey matter changes, suggesting that CBT affects the brain in a different way than 
fluoxetine.
59
 
This effect does not vary significantly between specific SSRIs.
58,60-63
  Three SSRIS, fluoxetine, 
fluvoxamine, and sertraline, and the serotonergic tricyclic antidepressant (TCA) clomipramine have been 
FDA-approved for pediatric OCD.  Paroxetine is not recommended for pediatric patients due to concerns 
about agitation related to short half-life, and possible increased risk of suicidal ideation.
64
 See Table 2 for 
FDA-approved antidepressants for pediatric use, indicating approved diagnoses, age range, and 
recommended initial and target dosing per manufacturer’s label, based on available clinical trials.
65
   
While it is typically advised that an adequate SSRI trial for OCD takes 8-12 weeks, a recent meta-
analysis of nine OCD medication trials demonstrated that the greatest benefit was seen within two weeks 
of medication initiation.
66
 As in other meta-analyses, clomipramine was more effective versus placebo 
than SSRIs.  This may reflect the earlier release of clomipramine, when study patients were more likely to 
be serotonin reuptake inhibitor-naïve.   
While multiple controlled clinical trials have demonstrated that clomipramine is effective for 
pediatric OCD, arguably more so than SSRIs, SSRIs are the safer, preferred initial treatment.
67,68
 
Clomipramine’s side effects significantly limit its use, and regular monitoring of blood levels and 
electrocardiograms is required as TCAs can delay cardiac conduction, leading to torsades des pointes 
and sudden cardiac death.
69,70
  Patients on clomipramine also report anticholinergic adverse effects 
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typical of TCAs including sedation, fatigue, orthostatic hypotension, dizziness, dry mouth, constipation, 
and urinary retention.   
For patients whose OCD is not adequately treated with an SSRI plus ERP, augmentation with a 
low-dose atypical antipsychotic, either risperidone or aripiprazole, is recommended. The antipsychotics 
olanzapine and quetiapine did not prove effective compared to placebo.
71
 However, if SSRI monotherapy 
is insufficient, studies suggest that adding ERP is more effective than adding risperidone.
72,73
 
TS: Behavioral therapy/ Comprehensive Behavioral Intervention for Tics (CBIT)   
As with OCD, behavior therapy has consistently been shown through randomized controlled trials 
(RCTs) to be effective in the treatment of TS and tic disorders.  Habit reversal training (HRT) has 
emerged as the leading behavioral intervention,
74-77
 demonstrating medium to large effect sizes.
78 
 HRT is 
the primary component of Comprehensive Behavioral Intervention for Tics, 
79
 an empirically supported 
treatment for tics.
74,76,80,81
   Manualized CBIT is an 11-session treatment for both children and adults in 
which the goal is increased management and control over tics.  CBIT training for therapists is available 
through the Tourette Association of America, which was instrumental in the development of CBIT.
82
 
CBIT focuses on building tic awareness, which is necessary prior to the development and use of 
a competing response.
83-84
  During awareness training, individuals with tics learn to recognize when tics 
are experienced in addition to detecting the initial urge to tic (i.e., premonitory urge or “tic signal”). Once 
individuals are able to identify the signal for a tic and are highly aware of tic onset, a competing response 
can be designed. Competing responses are actions that are physically incompatible with the tic.  A child 
with a mouth-opening tic, for instance, could develop competing response of pressing his/her lips together 
until the urge to open the mouth fades. Use of the competing response in the moment is maintained until 
the urge to tic dissipates.  
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CBIT also utilizes other behavioral interventions alongside HRT, including functional analysis and 
relaxation training. Functional analysis is the identification of situational factors contributing to tic 
occurrence (antecedents) as well as environmental responses to the tics (consequences) that increase tic 
frequency or intensity. For example, monitoring of tics may indicate a child demonstrates more tics at 
school and when completing homework. This suggests that school stress is a likely antecedent.  
Encouraging the child to practice competing responses and relaxation strategies regularly at school and 
while doing homework can reduce stress, thereby, reducing tics.  Finally, relaxation training is provided to 
reduce anxiety, often an internal antecedent state exacerbating tics.  
It should be noted that other behavioral interventions have been developed to address tics 
including ERP (see TS and OCD:ERP) modified for tics, which has demonstrated efficacy,
80
 and less-
studied techniques such as contingency management training, relaxation training alone, and urge 
reduction. Few RCTs have compared the effects of pharmacological interventions to behavioral 
interventions for tics. 
85
. 
Stereotypic movement disorders (SMD)   
Patients with stereotypic movement disorders (SMD) have involuntary, repetitive movements with 
no obvious function.  These movements, or stereotypies, are patterned, rhythmic, purposeless and often 
result from internal stimulation.  Severe stereotypies interrupt daily functioning or result in self-injury.
86,87
  
There is no clear consensus about how to classify stereotypical movement disorders, and how severe 
they must be to constitute a disorder.
87
  Common stereotypies in SMD include head banging, body 
rocking, complex hand and arm movements, and self-biting.
86,88
   To meet criteria for SMD, the DSM (5
th
 
Edition) requires that the movements cause significant impairment, occur early in development and are 
not better explained by another neurodevelopmental or mental disorder or result from substance related 
or other neurological conditions.
86
 However, SMD may occur in the presence of genetic or 
neurodevelopmental disorders such as intellectual disability (ID).  Stereotypies occurring outside of the 
presence of a behavioral or neurological disorder are considered primary, while those occurring within the 
presence of these other disorders are deemed secondary.
87
 Secondary stereotypic movements are 
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frequently observed in autism spectrum disorder (ASD) as well as other developmental disorders, other 
psychogenic conditions, neurodegenerative disorders, metabolic disorders, traumatic brain injury, and 
substance-induced disorders.
88-91
 
For diagnostic and treatment purposes, it is essential to differentiate stereotypies from behaviors 
or movements resulting from other disorders (e.g., OCD, TS, and dyskinesia). Compared to tics, 
movements attributable to SMD typically have an earlier age of onset (< 3 years old) and occur in a more 
fixed and lengthier pattern.
86,87
 Stereotypies lack the premonitory urge or “tic signal” associated with many 
tics.
86  
 Movements associated with SMD are less likely to be perceived by the child as distressing and 
more likely to occur during periods of excitement.
87 
 Unlike compulsions in OCD, stereotypic movements 
are not used as a means of reducing distress from a specific, intrusive thought or to comply rigidly with 
rules, but rather appear purposeless. As discussed above, stereotypies are commonly found in 
individuals with ASD; the DSM-5 notes that a diagnosis of SMD in addition to ASD is warranted only 
when the stereotypies are self-injurious in nature or severe enough to be a primary target of treatment.
86
   
Stereotypies that are easily stopped by distraction and are not experienced as interfering or distressing 
are better understood as typically occurring repetitive movements or stereotypies not warranting 
diagnosis of SMD.
86 
 Although SMD must be distinguished from movement/behaviors resulting from other 
psychiatric conditions, SMD may be comorbid with neuropsychiatric diagnoses such as ADHD, tic 
disorders, developmental coordination disorder, and to a lesser degree, OCD.
86
  It is important to note 
that self-injurious stereotypies may not indicate depressive mood.
86
 
SMD: Behavioral strategies 
Multiple behavioral interventions have been developed to target and reduce stereotypic 
movements.  Research into the efficacy of these methods has been sparse but is growing.
88
 Interventions 
have developed from various interpretations of stereotypies and are not necessarily specific to 
stereotypies resulting solely from SMD.
92  
 As such, behavioral interventions for stereotypies in general 
will be reviewed below. Many argue that stereotypies persist as a result of continued reinforcement 
(internal and/or external). Therefore, functional analysis may be beneficial in reducing stereotypies or 
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related impairment by identifying antecedents and consequences, as in CBIT (described above).  With 
regard to consequences, functional analysis is particularly helpful in understanding the means by which 
the movement is reinforced and potentially perceived as functional.
90,92,93
  
Antecedent-based strategies have been developed to prevent the stereotypical movement from 
occurring by altering the environment.
90,92
 One major antecedent-based strategy is environmental 
enrichment, also understood as noncontingent reinforcement or alternative stimulation.
92,94 
 This involves 
providing access to other reinforcing or competing sensory stimuli for individuals with stereotypies, thus 
reducing occurrence of the stereotypy and its inherent reinforcement. Environmental enrichment requires 
the presence of various other forms of stimulation to be available in the environment that are equally, if 
not more, reinforcing than engaging in the stereotypic movement.  It is particularly beneficial to have 
alternative stimuli that are “matched” to the resulting sensory experiences of the stereotypic 
movement.
92,95 
 For example, for a child with mouth stereotypic movement, the family would give the child 
multiple toys that could provide in oral stimulation and does not give the child any social consequence if 
the child does engage in the stereotypy.  
Consequence-based strategies intervene in response to the target behavior. They may focus on 
sensory extinction, displacement of reinforcement, differential reinforcement, punishment (as understood 
in operant conditioning) or inhibitory stimulus control, or a combination of reinforcement and sensory 
extinction or punishment (i.e., response interruption and redirection).
92,96,97
 A combination of antecedent 
and consequence based strategies can also be used.
90,96,97 
 Additionally, there is evidence to suggest that 
behavior therapy with HRT has efficacy in treating stereotypic movements in individuals without ASD.
98,99 
 
See Table 3 for an overview of behavioral intervention techniques.  
For self-injurious stereotypies, which warrant their own specifier within the SMD diagnosis, 
special considerations may apply.  When prevention of harm to self or others is necessary, intervention 
becomes a greater priority. Response blocking and more consequence-based approaches may therefore 
be more appropriate in immediately preventing further harm to self.
101,102
   Response-blocking and 
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consequence-based approaches are the most frequently studied interventions for self-injurious behavior 
in children with developmental disabilities.
101 
  
Sydenham chorea  
Like TS, Sydenham chorea (SC) is a movement disorder with significant psychiatric comorbidity.  
SC is triggered by group A beta-hemolytic streptococcal infection, as is rheumatic fever (RF). 
Neuropsychiatric comorbidity is common in both RF and SC, but more common with SC.  Common SC 
comorbidities include anxiety, depression, and ADHD, in addition to new-onset OCD.
103-106
 Additional 
symptoms of SC include obsessive-compulsive spectrum disorders, hypotonia, involuntary movement, 
decreased coordination, fine motor impairment, weakness, and involuntary relaxation.  Phonemic verbal 
fluency may be reduced (words with a given letter), but not semantic verbal fluency (words in a particular 
category) after controlling for age and education.
105,107-110
  The development of comorbidities is also 
influenced by genetic predisposition, developmental level, and gender.
111
  Children with premorbid ADHD 
have been shown to be at increased risk of developing SC.
104
 SC movement and psychiatric symptoms 
can be quite persistent, with over 72% reporting persistent symptoms after 2.7 years.
111
 
Interestingly, SC and TS typically present in childhood and affect the basal ganglia and related 
cortical and thalamic areas.
112
   Pediatric autoimmune neuropsychiatric disorders associated with 
streptococcal infection (PANDAS) are likely related to SC.
113-115
   
SC: Management of comorbidities 
Management of the neuropsychiatric comorbidities of SC focuses on eliminating the streptococcal 
infection and preventing recurrence.
107 
To date, no guidelines or standardized recommendations exist due 
to lack of sufficient quality research of the various management strategies.  
The first-line intervention for SC is acute treatment of the streptococcal infection.
116,117 
 The 
American Academy of Pediatrics Red Book also recommends long-term continuous prophylaxis to 
prevent disease recurrence and for cardiac protection. This secondary prophylaxis significantly decreases 
both disease recurrence and neuropsychiatric exacerbations, and is recommended for a minimum of 5 
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years or until age 21 years (whichever is longer), and potentially for life in those with rheumatic heart 
disease.
112,118 
 Penicillin G prophylaxis may reduce SC recurrence and neuropsychiatric exacerbations in 
children.
119
  
Symptomatic management is also important. Symptoms tend to improve with rest and sleep. In 
contrast, intentional movement, excitement, and stress tend to aggravate symptoms.
107
  
Insufficient evidence exists regarding symptomatic medication use. “Off-label” medication use 
must be slowly titrated since the risk of adverse effects is greater in those with SC compared to healthy 
controls. Sodium valproate, which raises brain GABA levels, has the potential to improve hyperactivity, 
aggression, irritability and impulsivity.
120 
 Low-dose risperidone, haloperidol, and pimozide may also 
improve symptoms.
107,109,120 
 SSRIs have not been studied in SC.   
Immunological interventions that target the humorally-mediated autoimmune response have also 
been studied, including intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange.
112,121
  
These studies have been small and level of evidence is not high.  In a cross-sectional study, 17 children 
with SC were treated with IVIG, compared to a standard treatment SC group (n=9) and non-SC group 
(n=17).  Six months after treatment, the IVIG group showed fewer behavior difficulties, less impulsivity, 
and better cooperation and executive functioning compared to the standard treatment group.
122   
Studies 
of IVIG treatment of the streptococcal-related autoimmune disease, PANDAS, have been mixed.  One 
small study reported improvement in neuropsychiatric symptoms including anxiety, depression, 
obsession, compulsion, impairment, and overall severity after IVIG (n=9) or plasmapheresis (n=10).
123,124 
 
Recently, a randomized controlled study of IVIG for PANDAS in 35 children failed to demonstrate that 
IVIG was more effective than placebo.
125
  Gadian et al.
121
 reviewed the literature, which suggested that 
IVIG may speed recovery in SC, and recommended that IVIG be considered in severe cases of SC 
(grade C evidence). 
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The management of neuropsychiatric symptoms in SC requires communication between a 
multidisciplinary team including patient, family, clinicians, and teachers. Psychoeducation and cognitive 
behavioral therapy is appropriate.
107
  
Juvenile-onset Huntington’s disease 
Unlike SC, HD is not post-infectious, and typically manifests in adulthood.  Approximately 5-7% of 
patients with HD have onset before the age of 21 years, 80% of whom received the gene through 
paternal transmission.
126
  In Ribai et al.’s
127
 large series of 1452 Huntington’s patients, 2% had symptom 
onset before the age of 20.   
Family history positive for HD is a key diagnostic feature in pediatric patients.  However, children 
occasionally present with symptoms before their affected parents manifest symptoms, family history is not 
known, or the history is not revealed to the treatment team.
127
   
 Psychiatric manifestations of juvenile HD appear to vary with age of onset and may precede clear 
motor symptoms such as chorea.  In a series of 12 juvenile patients with HD, symptoms upon first 
presentation were assessed.
128
 Patients under 10 years of age presented with cognitive dysfunction as 
the first symptom in 71% and behavioral symptoms in 58%.  Most of these young patients were 
symptomatic by 5 years of age.  Two of the 12 children in the series were initially diagnosed with ADHD 
and one with motor tics. 
Adolescent-onset (10 years of age and older) HD patients are more likely than younger patients 
to present with oropharyngeal dysfunction as the first sign of disease.  Cognitive symptoms were reported 
at initial presentation in 40% of cases, and behavioral symptoms in 17% of the above patient series.  
Testing revealed serial declines in Wechsler verbal, performance, and full-scale intellectual quotients.
128
  
Letort et al.
129
 described heterogeneous symptoms in adolescent-onset HD, including substance misuse, 
recurrent suicidality, hyperactivity, and personality disorder.  Other severe behaviors requiring “medical or 
legal intervention” in HD-affected teenagers include arson and sexual misconduct.
126
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In Ribai’s series of 29 patients with juvenile-onset HC, behavioral disturbance was reported in 
79% of patients, and cognitive decline in 100%.
127
 Many of these young patients had quite severe 
psychiatric symptoms, sometimes for many years before they manifested chorea.  Severe developmental 
delays and substance use disorders were each reported in 10.3% of patients in this series.  Other serious 
symptoms included psychosis, recurrent suicide attempts, and anorexia.  Ribai’s group suggested that 
HD “be considered as a diagnostic hypothesis in a child or young adult with an atypical movement 
disorder and severe, progressive psychiatric or cognitive disturbances, even in the absence of an HD-
positive family history”.
127 
  Atypical behavioral presentations should spur inquiry into the reason for non-
custodial parents’ absence (e.g., institutionalization, imprisonment, death) that might suggest an HD 
diagnosis.   
Timing of psychiatric symptoms in juvenile-onset HD may also be atypical versus usual 
presentation of primary psychiatric disorders.  For instance, selective mutism classically presents by the 
time of school entrance, around age 4-6 years of age, but has been reported to present later, in the 
context of mood symptoms, in children who developed HD with oropharyngeal dysfunction.
131,132
   
When teens from HD-affected families develop mood or behavioral problems, it is important to 
assess the home environment.  HD-unaffected adolescents living with HD-affected relatives face 
significant stressors not impacting typical teenagers.  If a teen is living with an older, more severely 
affected relative, the teen may experience stress from caring for the affected relative and living in a 
disrupted home environment.  This stress may trigger depression, with resultant mood and behavior 
symptoms not due to HD.
130
   In one study, teens from HD families who completed home interviews 
described struggling to provide home care for affected relatives.  Some of them missed a significant 
amount of school until the family was able to obtain paid caregivers.  Many teens reported frequent worry 
about their own health and HD status.  Some reported abuse by affected parents.
133
 Most teens 
interviewed in HD focus groups had not met other teens from affected families and reported feeling 
isolated from affected and non-affected parents and from their peers.
134
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Treatment of psychiatric symptoms in HD is not well-established in any age group, and the 
pediatric literature consists of case reports.  In the absence of clear guidance from the research literature, 
some authors have advised treating isolated psychiatric symptoms in children and teenagers from HD 
families “as though the primary inciting factors are social or environmental, and then reassessing 
neurological and cognitive function in 6-12 months.  Progression of neurologic symptoms, despite optimal 
psychological and social management, helps to support a formal diagnosis of HD”.
126
    
Antipsychotics, antidepressants, mood stabilizers and anticonvulsants have been reported as 
symptomatic agents for psychiatric symptoms in HD.
129
 Two agents are approved for HD movements in 
adults, tetrabenazine and deutetrabenazine.  Both agents carry black box warnings for depression and 
suicidality, but rate of these symptoms is significantly lower with deutetrabenazine.
129,135
  One case report 
cited successful treatment of psychotic depression in a 12-year-old who was refusing to eat, suffering 
delusions of being poisoned with amitriptyline plus tetrabenazine.  This combination would require close 
monitoring, as both the antidepressant and tetrabenazine prolong the corrected QT interval.
132
   In 
another case report, an 8-year-old with HD initially diagnosed with ADHD did not fare so well on 
methylphenidate.  The child demonstrated a rapid decline in fine motor skills, and developed dysarthria, 
hypertonia and motor impersistence within 4 weeks of starting the stimulant.  After these adverse effects 
appeared, the family disclosed a previously-unreported paternal history of HD, triggering concerns that 
“stimulant-induced hyperdopaminergic toxicity accelerated the rate of neurodegeneration”.
136
  
Dopamine-depleting or –blocking agents may exacerbate dystonia and rigidity in HD.
126
    
However, second-generation antipsychotics have proven helpful for severe aggression and agitation in 
HD.  A risperidone study of 5 HD patients included one juvenile patient, a 17-year-old with previous 
diagnoses of conduct disorder and learning disability.  He had a significant decline in aggression on long-
acting injectable risperidone, which was started due to noncompliance with oral medication.
130
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Neurodegeneration with brain iron accumulation 
Psychiatric symptoms are prevalent in several childhood disorders of neurodegeneration with 
brain iron accumulation (NBIAs). These disorders are much rarer than TS, SC, and HD.  One such 
disorder, pantothenate kinase-associated neurodegeneration (PKAN) can present with symptoms of 
psychiatric disorders with known basal ganglia dysfunction, such as OCD and tic disorders. Children who 
lose the ability to speak due to an NBIA are occasionally diagnosed with selective mutism or severe 
depression, although the motor signs of NBIAs are not features of psychiatric mutism or depression.  
Brain magnetic resonance imaging (MRI) demonstrates iron accumulation and is a key tool for diagnosis 
of NBIA.
137
 
PKAN, previously known as Hallervorden-Spatz syndrome, is a rare autosomal recessive 
disorder of basal ganglia iron deposition caused by mutations in the pantothenate kinase 2 (PANK2) 
gene.
138,139
  Classic and atypical subtypes of PKAN have been reported, as well as patients who appear 
intermediate in type.
140
  Classic PKAN presents in the first decade of life.  PKAN rapidly progresses to 
loss of ambulation and premature death.  Psychiatric symptoms are not typically reported.  Atypical PKAN 
presents later, in the second or third decade, with less severe neurologic symptoms, slower symptom 
progression, and more frequent psychiatric symptoms or comorbidity.
141
   Patients with atypical PKAN 
exhibit dystonia, choreoathetosis, a range of speech symptoms including ultimate loss of speech, and 
gradual gait disturbance, with loss of ambulation 15-40 years after presentation.
137
   
 Structured psychiatric assessment of children with NBIA, screening systematically for a range of 
disorders, has not been reported.  While two case series provide some details of psychiatric 
manifestations of PKAN, methods of ascertainment are unclear.  In one series of 16 juvenile patients with 
PKAN, eight had psychiatric symptoms, including OCD (5 patients), behavior problems (4), hyperactivity 
(3), tics (2) and depression (1).
140
 OCD and tics were not reported in another case series of 22 patients 
from ten families, although it is not clear these symptoms were investigated. Six of these patients were 
reported to have psychiatric issues, including emotional lability, impulsivity, and inattention.
142
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PKAN can prove a diagnostic challenge and may masquerade as an atypical presentation of 
many psychiatric disorders.  Two case reports illustrate patients with PKAN-related loss of speech, initially 
diagnosed as a conversion disorder in one case
143
  and selective mutism in another.
144
  Each of the latter 
two patients presented with mutism (at ages 11 years and 16 years, respectively) many years after the 
typical onset of functional selective mutism (before 5 years).
145
  Children with functional selective mutism 
almost always retain their typical speech with first-degree relatives in their homes, and do not exhibit a 
decline in speech skills. 
The Vansteenkiste case report described a woman who developed progressive speech problems 
and involuntary arm movements at 11 years of age.  She was correctly diagnosed with PKAN by brain 
MRI at age 28, “after several evaluations by psychiatrists and neurologists for her alleged conversion 
disorder”.   While she had symptoms of several psychiatric disorders, her presentation was not classic for 
any of them, likely triggering the conversion disorder diagnosis.  At that time of her successful PKAN 
diagnosis, she was near-mute, relying on her phone for communication.  She “showed frequent repetitive 
stereotypical movements: stretching, touching her nose, waving and squeezing the hands.  The 
movements appeared as complex motor tics, but no tics were seen in her face”.
143
  This movement 
pattern differentiated her from patients with typical tic disorders, who almost always present with early and 
persistent motor tics involving the face, especially blinking.
146
   Another adolescent patient with PKAN has 
been described as demonstrating similar face-touching movements.
139
 
Treatment of the psychiatric manifestations of pediatric PKAN has been reported only rarely.  A 
boy who had been diagnosed with PKAN at 10 years of age presented emergently with prominent 
auditory hallucinations at 14 years of age.  He had no family history of psychosis.  He had been severely 
anxious for the preceding four months, worried about the “forthcoming destruction of the world”.  The teen 
communicated by writing, describing fears that birds would kill him.  He responded favorably to the 
antipsychotic olanzapine.
147
   
The patient diagnosed with selective mutism reported above was initially treated with fluoxetine 
and weekly psychotherapy for the mutism and severe depression.  That treatment proved unsuccessful.  
His inappropriate affect and the “extreme poverty of content” of his speech were concerning for the 
development of psychotic depression.  He was treated with olanzapine augmentation of the fluoxetine, 
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then with a second trial of venlafaxine and aripiprazole.  On the aripiprazole, the patient developed 
bilateral lower extremity dystonia which persisted off aripiprazole, and PKAN was ultimately diagnosed 
following brain MRI.  Rigidity and dysphagia improved on a regimen of botulinum toxin, tetrabenazine, 
clonazepam and biperiden, but mutism persisted.
144
  
CONCLUSION 
Providers treating children with movement disorders can best serve them by understanding the 
complex interplay of psychiatric symptoms and movements in these conditions.  Psychotherapy and 
psychiatric medications may directly improve some movements.  However, treatment of comorbid anxiety, 
depression, ADHD, and obsessive-compulsive symptoms may provide as much or more symptom relief 
for many young patients.  In addition, understanding the stress children and teens face when growing up 
in families with multigenerational movement disorders can lead to better care for patients with movement 
disorders.  Providers should be vigilant regarding atypical behavioral presentations or unusual motor 
features that may be early signs of neurodegenerative disorders. Pediatric neurologists and child and 
adolescent psychiatrists may need to work in consultation to develop the best team approach for many 
children with movement disorders. 
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Table 1.  Psychiatric comorbidities of juvenile Tourette syndrome in Tourette Syndrome International 
Database Consortium (TIC) database
1
 
Psychiatric comorbidity Percentage 
None (Tourette syndrome only) 25.3% 
ADHD (+/- OCD) 61.2% 
OCD (+/- ADHD) 19.2% 
OCD + ADHD 13.2% 
Anxiety  15.3% 
Conduct disorder/oppositional 
defiant disorder 
 
14.5% 
Mood disorder 12.2% 
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Table 2. FDA-approved pediatric antidepressants for major depression and obsessive-compulsive 
disorder
65
  
Drug Class Indication Age Initial Dose Target dose Titration 
Fluoxetine SSRI OCD 7-17 years 10 to 20 
mg/day 
10-60 mg/day  
MDD 8-18 years 10 mg/day 10 to 60 mg/day  
Escitalopram SSRI MDD 12-17 
years 
10 mg/day 10 to 20 mg/day  
Sertraline 
 
SSRI MDD, 
OCD 
6-17 years 25 mg /day 
(6-12 years), 
or 50 mg/day 
(13-17 years) 
200 mg/day  
Fluvoxamine SSRI OCD 8-17 years 25 mg at 
bedtime 
200 mg/day (8-11 
years), or 
300mg/day (12-17 
years).  
Increase by 25 
mg every 4 to 7 
days. Divide BID 
for doses over 
50 mg. 
Clomipramine TCA OCD 10-17 
years 
25 mg/day 3 mg/kg:  up to 200 
mg/day 
Do not exceed 
100 mg/day in 
first 2 weeks 
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Table 3.  Behavioral interventions for stereotypical movements. 
Antecedent-Based Intervention before target behavior. Noncontingent reinforcement or 
environmental enrichment.  Provides 
competing sensory stimuli, preventing 
stereotypy
92,94
 
Consequence-
Based 
Intervention in response to 
stereotypy. 
Sensory extinction and punishment.  Includes 
response blocking (physically blocking head-
banging)
92
, or pairing aversive stimuli with 
stereotypy (sounding buzzer to decrease 
movement)
92,94
. 
Reinforcement strategies. Reinforcing other 
behaviors performed instead of stereotypy, or 
displacement of reinforcement
92,94
. 
Reinforcement and punishment combination 
strategies.  Response interruption and 
redirection (RIRD) combines sensory 
extinction or punishment with differential 
reinforcement
92,94,96
. 
Antecedent and 
Consequence 
Combination of noncontingent and 
contingent strategies. 
RIRD.  May be combined with contingent 
reinforcement (see above) or with 
noncontingent reinforcement
90,96
. 
Other Modified behavioral interventions Modified habit reversal with differential 
reinforcement.  Periods of awareness training 
and consequence-based reinforcement are 
provided by parents
98
. 
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